Follow us on Twitter
This page is updated frequently with new Leukemia-related patents. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds.
Subscribe to updates on this page: Leukemia RSS
|| List of recent Leukemia-related patents
|Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells|
The present invention is directed to a method of deriving pluripotent embryonic stem cells from mouse blastocysts or from primordial germ cells from a post-implantation mouse embryo, or of maintaining or growing pluripotent embryonic stem cells from a mouse, or of expanding human hematopoietic stem cells or human hematopoietic precursor cells. The methods include the step of cultivating the stem cells or precursor cells for at least one passage in a culture medium preconditioned by the rabbit fibroblast cell line rab9 (atcc catalogue crl1414) and containing less than 0.1 ng/ml leukemia inhibitory factor (lif)..
|Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia|
A first aspect of the invention relates to a method of treating aml in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; and wherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.. .
|Genetically modified mice and engraftment|
A mouse with a humanization of the mil-3 gene and the mgm-csf gene, a knockout of a mrag gene, and a knockout of a mil2rg subunit gene; and optionally a humanization of the tpo gene is described. A rag/il2rg ko/htpo knock-in mouse is described.
|Anti-cancer activity of novel bicyclic heterocycles|
The present invention relates to compound of formula i, ii, iii, or iv, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, formulas (i), (ii), (iii) and (iv) wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r11, and r12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders.
|Chalcone derivatives as nrf2 activators|
Compounds and methods for treating or preventing a disease, disorder or condition associated with an nrf2-regulated pathway, including those associated with an autoimmune disease, comorbidity associated with diabetes, such as retinopathy and nephropathy, bone marrow transplant for leukemia and related cancers, bone marrow deficiencies, inborn errors of metabolism, and other immune disorders, oxidative stress, respiratory infection, ischemia, neurodegenerative disorders, radiation injury, neutropenia caused by chemotherapy, autoimmunity, and congenital neutropenic disorders, and for restoring a corticosteroid responsiveness, in a subject are provided.. .
|Compounds for use in the treatment of feline retroviral infections|
The present invention relates to compounds and compositions for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of said derivatives for the manufacture of a medicament for the treatment or prevention of feline leukemia virus (felv) infections occurring alone or together with feline immunodeficiency virus (fiv) infections in cats.. .
|Methods of treating acute myeloid leukemia by blocking cd47|
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
|Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias|
The present invention relates to a method of treating a warm-blooded animal, especially a human, having mixed lineage leukemia (mll rearranged all) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially pkc412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of mll rearranged all; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of mll rearranged all.. .
|Compositions and methods of aloe polysaccharides|
The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis c..
|Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties|
Hybrid molecules comprising a retinoic acid receptor agonist moiety and a histone deacetylase inhibitor (hdac) moiety are disclosed. Hybrid molecule 3 (6-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)naphthalene-2-hydroxamic acid) was proven to posses hdac activity while maintaining rar agonist activity.
|Therapies for treating cancer|
Provided herein are methods that relate to a novel therapeutic strategy for treatment of cancer, including hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In particular, the method includes administration of a pi3kδ inhibitor and a syk inhibitor..
|Aminooxazole inhibitors of cyclin dependent kinases|
Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, cns cancer, melanoma, ovarian cancer, and renal cancer..
|Pharmaceutical composition comprising tpo or an agonist of the tpo receptor|
The present invention relates to a new use of tpo or a tpo/mpl receptor agonist as an adjuvant of a treatment of a neoplastic disease by irradiation or chemotherapeutic agents in order to prevent genomic instability of hematopoietic stem cells incurred through radio- or chemotherapy and hence to prevent the occurrence of secondary cancers, namely acute myelogenous leukemia and myelodisplasia.. .
|Compounds and methods for kinase modulation, and indications therefor|
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on fms protein kinase, or on fms and kit protein kinase, or on fms and flt-3 protein kinase.
|Diagnostic and therapeutic targets for leukemia|
The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and hoxa5 promoter activity.. .
|Therapeutic method and medicament for htlv-1 associated myelopathy (ham)|
The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human t cell leukemia virus type-1 associated myelopathy (ham) patients and asymptomatic htlv-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human t cell leukemia virus type-1 (htlv-1) associated myelopathy (ham) patients and asymptomatic htlv-1 carriers (acs), which is characterized by reducing htlv-1 virus-infected cells using an anti-human cc-chemokine receptor 4 (ccr4) antibody..
|Therapy for leukemia|
A pharmaceutically acceptable composition and method for leukemia therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-fos, (b) an inhibitor of dusp-1, and (c) an inhibitor of bcr-abl tyrosine kinase.
|Heterocyclic compounds and their uses|
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer..
|Methods and compositions to eliminate chronic lymphocytic leukemia and other hematologic malignant cells in stromal microenvironment for cancer therapy|
The present invention regards compositions and methods for treating chronic lymphocytic leukemia in the in vivo tissue environment using selenium-containing compositions. In particular aspects, a selenium-comprising compound is administered to an individual wherein the cll cells are in a stromal cell environment, wherein stromal factors modulate the selenium comprising compound to enhance its activity..
|Compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
|Substituted fused tricyclic compounds, compositions and medicinal applications thereof|
The present invention relates to substituted fused tricyclic compounds of formula (i) or (ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by jak activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity.
|Compositions and methods for diagnosing cancer|
The application describes methods for diagnosing subjects with leukemia by detecting fusion genes associated with the onset of leukemia.. .
|Chronic lymphocytic leukemia (cll) biomarkers|
The present application describes chronic lymphocytic leukemia (cll) biomarkers. In particular, the invention concerns mirna151 3p, mirna409 3p, ptk2, and/or pi3k as biomarkers for patient selection in cll, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, and methods of advertising related thereto..
|Compositions and methods for treating leukemia|
The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.. .
Where the prescribed substituent groups are defined, are useful in treating or preventing cancer. In particular, the compounds and their pharmaceutical compositions are useful for treating relapsed/refractory acute myeloid and lymphoid leukemia and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas..
|Method for decreasing low density lipoprotein levels|
The present invention features, in certain aspects, methods of promoting endocytosis of ldl with α1pi or peptides derived from α1pi. The present invention also provides methods for decreasing ldl levels in response to α1pi augmentation therapy.
|Methods for treating leukemia and disorders mediated by cbfbeta and runx1 proteins|
A method for treating core binding factor (cbf) leukemia in a subject, comprising administering to a subject having cbf leukemia a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt or ester thereof, that inhibits cbfβ and runx1 binding in the subject, thereby treating the cbf leukemia.. .
|Stabilization of the anti-cd20 antibody rituximab|
The invention provides isolated stabilized anti-cd20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.. .
|Methods and compositions for the diagnosis and treatment of chronic myeloid leukemia and acute lymphoblastic leukemia|
Compositions and methods for the identification, prognosis, classification, treatment, and diagnosis of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of various genomic abnormalities of the ikzf1 gene which are shown herein to be associated with acute lymphoblastic leukemia (all), more particularly, associated with bcr-abl1 positive all and/or shown to be associated with chronic myeloid leukemia (cml), more particularly, associated with blast crisis chronic myeloid leukemia (bc-cml) and/or the likelihood of progression into blastic transformation of cml.
|Formulation comprising phenylaminopyrimidine derivative as active agent|
An oral pharmaceutical formulation containing an effective amount of nrc-an-019 including its pharmaceutically acceptable salts and polymorphs such as form i, form ii and form iii thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing nrc-an-019 in an effective concentration for the better therapy against chronic myeloid leukemia as bcr-abl tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like..
|Compounds and methods for targeting leukemic stem cells|
This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.. .
|Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells|
This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, cd 54, cam, elastin and fak; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, cns cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer.. .
|Treatment of cancer with dopamine receptor antagonists|
Described are methods of treating a cancer comprising administering to a subject in need thereof an effective amount of a dopamine receptor (dr) antagonist. The dr antagonist may be a phenothiazine derivative, such as thioridazine or chlorpromazine.
|Prodrug of an ice inhibitor|
Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .
|Mutants of l-asparaginase|
The present invention relates to a novel mutant of l-asparaginase enzyme characterized in having high thermostability, ph stability and no glutaminase activity useful for therapeutics and the process of preparing the same. The present invention specifically relates to mutant's mtcc 5580, mtcc 5581 and mtcc 5582 characterized in having higher stability, no glutaminase activity etc., to allow their usage in the form of improved protein therapeutics.
|Treatment of acute lymphoblastic leukemia|
The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (all), the method comprising the administration of a pharmaceutical composition comprising a cd19xcd3 bispecific single chain antibody construct to an adult patient in the need thereof.. .
|Use of artemisine derivatives and pharmaceutical salts thereof|
The invention demonstrates the application of an artemisinin derivative and its pharmaceutical salt. The artemisinin derivatives diarteether amine and its pharmaceutical salt inhibit the proliferation of leukemic cells, block the cell cycle of leukemic cells and induce the apoptosis of leukemic cells.
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patents related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.